ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4000 participants.
Also called NCT06320431
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,000 participants
- Registry
-
NCT06320431
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT06320431. Randomized; single masking; primary purpose treatment. Start 2024-09-26 (actual); primary completion 2030-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
- Acronym
- ACT-WHEN
- Condition
- Acute Ischemic Stroke AIS
- Condition
- Stroke Acute
- Condition
- Stroke, Acute, Stroke Ischemic
- Intervention (Drug)
- Tenecteplase
- Lead sponsor
- University of Calgary
- Collaborator
- The George Institute for Global Health, Australia
Record details
- Record id
cardio:ct-nct06320431- Content hash
209162d3933682ff1d7105983388786f5eecd9feb4164fad1d8832ec81db6a4a